Review
Published on 12 Apr 2022
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
in Alzheimer's Disease and Related Dementias
![Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab](https://www.frontiersin.org/files/myhome article library/870517/870517_Thumb_400.jpg)
- 54,275 views
- 131 citations